Search results for #glofitamab
Kala Me lowen dhywgh hwi oll / happy Mayday. I’m celebrating with cycle 7 of #glofitamab for relapsed non-Hodgkin #lymphoma at @RCHTWeCare in #Kernow.
Look out for this at #ASCO24 Important update for #glofitamab in R/R #MCL
Great to see our consensus guidelines on CD20x3 #bispecific safety management in a nice PDF @BloodJournal bit.ly/3SvFfhl. Hopefully a useful resource for the roll out of these potent drugs #lymsm #glofitamab #Epcoritamab #mosunetuzumab
既治療で移植適応がない再発・難治性 #びまん性大細胞型B細胞性リンパ腫 に、CD20とCD3に対する二重特異性抗体 #glofitamab とゲムシタビン/オキサリプラチン併用はリツキシマブとゲムシタビン/オキサリプラチンの併用よりも有意に全生存期間を延長できることが分かりました medical.nikkeibp.co.jp/leaf/all/cance…
#Hematology #Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS #lymphoma | @BloodJournal | American Society of Hematology @ASH_hematology #lymsm ashpublications.org/blood/article/…
Im on brand new licensed #chemotherapy drug for relapsing #lymphoma. After cycle 3, it’s going fairly well. #glofitamab so far only left me with 3 main side-fx - #fatigue, squits & #neuropathy. I’ve 9 cycles to go. Updates to follow. @macmillancancer @LymphomaAction #cancer
Cycle 3 of #glofitamab #chemotherapy today at #Treliske. #lymphoma @LymphomaAction
Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Glofitamab - Blood Cancers OncTalk 2023 youtu.be/WyQ7icpRWZs?si… via @YouTube In this video, Dr. @LymphClinician discusses #glofitamab as a treatment option for patients with NHL, as well as side effects such as CRS. For…
At the #ASH2023 Meeting, Martin Hutchings, MD, PhD, discussed updated data on the combination of #glofitamab plus polatuzumab vedotin among heavily pretreated patients with diffuse large B-cell lymphoma. Learn more: hmpgloballearningnetwork.com/site/onc/video… @ASH_hematology @DocHutchings
La Ud. de #OncoHematologia del HNJS en colaboración @fibhnjs y la farmacéutica ROCHE FARMA SA, han puesto en marcha un #estudio para evaluar la eficacia de #glofitamab en combinación con quimio inmunoterapia en pacientes pediátricos y adultos jóvenes con linfoma no Hodgkin
Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by @FDAOncology in 2023: 1. #Zanubrutinib 2. #Pirtobrutinib 3. #Polatuzumab 4. #Epcortimab 5. #Glofitamab 6. #Quizartinib 7. #Talquetamab 8. #Elranatamab 9. #Ivosidenib #HemeTwitter #Oncology
Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by @FDAOncology in 2023: 1. #Zanubrutinib 2. #Pirtobrutinib 3. #Polatuzumab 4. #Epcortimab 5. #Glofitamab 6. #Quizartinib 7. #Talquetamab 8. #Elranatamab 9. #Ivosidenib #HemeTwitter #Oncology
Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by @FDAOncology in 2023: 1. #Zanubrutinib 2. #Pirtobrutinib 3. #Polatuzumab 4. #Epcortimab 5. #Glofitamab 6. #Quizartinib 7. #Talquetamab 8. #Elranatamab 9. #Ivosidenib #HemeTwitter #MedTwitter…
Although many patients with diffuse large B-cell #lymphoma respond well to their initial therapy, 35% treated with the standard treatment experience refractory disease or #relapse. One therapy being evaluated is #glofitamab. Read more: ow.ly/R7ae50Q7G97 #DLBCL
#Roche has submitted a BLA for #Mosunetuzumab (#莫妥珠单抗) in China. As a reference, the BLA for #Glofitamab was approved 9 months (2023.2-2023.11) after its first application.
Although many patients with diffuse large B-cell #lymphoma respond well to their initial therapy, 35% treated with the standard treatment experience refractory disease or #relapse. One therapy being evaluated is #glofitamab. Read more: ow.ly/R7ae50Q7G97 #DLBCL
#epcoritamab vs #glofitamab battle of the bispecifics. hopefully the first of many collabs with @VictoriaNachar 👏🤓😎 #lymsm #oncopharm tandfonline.com/doi/full/10.10…
